INDIANAPOLIS, Jan. 25,
2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:
LLY) today announced that Johna
Norton, executive vice president of Global Quality, will be
retiring after 34 years of service with the company, effective
July 31, 2024.
She will continue to serve at full capacity in her role and as a
member of Lilly's Executive Committee until her retirement date. An
internal and external search is actively underway for her
successor.
"Johna's career has been built on her commitment to ensuring
that our medicines are produced with the highest quality standards.
By ensuring our company, manufacturing sites, production lines,
team members and collaborators share this commitment, she has had a
profound and positive impact on patients and our company," said
David A. Ricks, Lilly's Chair and
CEO. "During her tenure as leader of Global Quality, Johna has
overseen significant expansion, modernization of systems and
improvements in our processes and team. On behalf of our Board,
leadership team, and the thousands of employees who have worked
with Johna, I want to extend my heartfelt gratitude to her for her
many years of outstanding service to Lilly."
Norton has been with Lilly since 1990, starting as an analytical
chemist and moving on to hold various leadership positions in
quality assurance and quality control. She has supported research
and development and commercial manufacturing at numerous Lilly
facilities and with external manufacturing partners around the
world. Norton played a key role in the successful transition of new
molecules from development to manufacturing and the implementation
of continuous manufacturing processes. As a quality leader at
Lilly's Indianapolis and
Ireland manufacturing facilities,
she led work on the production of Lilly's first monoclonal
antibodies for clinical trials and the build and qualification of
the first monoclonal facility in Ireland. In 2017, Norton was named one of the
Top Women in Life Sciences by FiercePharma.
About Lilly
Lilly is a medicine company turning science into healing to
make life better for people around the world. We've been pioneering
life-changing discoveries for nearly 150 years, and today our
medicines help more than 51 million people across the globe.
Harnessing the power of biotechnology, chemistry and genetic
medicine, our scientists are urgently advancing new discoveries to
solve some of the world's most significant health challenges:
redefining diabetes care; treating obesity and curtailing its most
devastating long-term effects; advancing the fight against
Alzheimer's disease; providing solutions to some of the most
debilitating immune system disorders; and transforming the most
difficult-to-treat cancers into manageable diseases. With each step
toward a healthier world, we're motivated by one thing: making life
better for millions more people. That includes delivering
innovative clinical trials that reflect the diversity of our world
and working to ensure our medicines are accessible and affordable.
To learn more, visit Lilly.com and
Lilly.com/news, or follow us
on Facebook, Instagram and
LinkedIn. C-LLY
Lilly Cautionary Statement Regarding Forward-Looking
Statements
This press release contains certain forward-looking statements
regarding leadership changes and expectations for the future.
All statements other than statements of historical fact are
statements that could be deemed forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. The words
"will", "anticipate" and similar expressions are intended to
identify forward-looking statements. Actual results may differ
materially due to various factors. The following include some but
not all of the factors that could cause actual results or events to
differ materially from those anticipated, including the significant
costs and uncertainties in the pharmaceutical research and
development process, including with respect to the timing and
process of obtaining regulatory approvals; the impact and outcome
of acquisitions and business development transactions and related
costs; the expiration of intellectual property protection for
certain of the company's products and competition from generic
and/or biosimilar products; the company's ability to protect and
enforce patents and other intellectual property; changes in patent
law or regulations related to data package exclusivity; competitive
developments affecting current products and the company's pipeline;
market uptake of recently launched products; information technology
system inadequacies, breaches, or operating failures; unauthorized
access, disclosure, misappropriation, or compromise of confidential
information or other data stored in the company's information
technology systems, networks, and facilities, or those of third
parties with whom the company shares its data; the impact of global
macroeconomic conditions, trade disruptions, disputes, unrest, war,
regional dependencies, or other costs, uncertainties and risks
related to engaging in business globally; unexpected safety or
efficacy concerns associated with the company's products;
litigation, investigations, or other similar proceedings involving
past, current, or future products or commercial activities as the
company is largely self-insured; issues with product supply and
regulatory approvals stemming from manufacturing difficulties,
disruptions, or shortages, including as a result of
unpredictability and variability in demand, labor shortages,
third-party performance, quality, or regulatory actions related to
our facilities; dependence on certain products for a significant
percentage of our total revenue and an increasingly consolidated
supply chain; reliance on third-party relationships and outsourcing
arrangements; the impact of public health outbreaks, epidemics, or
pandemics, such as the COVID-19 pandemic; regulatory changes or
other developments; regulatory actions regarding operations and
products; continued pricing pressures and the impact of actions of
governmental and private payers affecting pricing of, reimbursement
for, and access to pharmaceuticals; devaluations in foreign
currency exchange rates or changes in interest rates and inflation;
changes in tax law, tax rates, or events that differ from the
company's assumptions related to tax positions; asset impairments
and restructuring charges; changes in accounting and reporting
standards promulgated by the Financial Accounting Standards Board
and the Securities and Exchange Commission (SEC); regulatory
compliance problems or government investigations; and actual or
perceived deviation from environmental-, social-, or
governance-related requirements or expectations. For additional
information about the factors that could cause actual results or
events to differ materially from forward-looking statements, please
see the company's latest Form 10-K and subsequent Forms 8-K and
10-Q filed with the SEC. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
release. Except as is required by law, the company expressly
disclaims any obligation to publicly release any revisions to
forward-looking statements to reflect events after the date of this
release.
Refer to:
|
Tarsis
Lopez; tarsis.lopez@lilly.com; 224-406-2746
(Media)
|
|
Joe
Fletcher; jfletcher@lilly.com; 317-296-2884
(Investors)
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/johna-norton-to-retire-as-lilly-executive-vice-president-of-global-quality-302043876.html
SOURCE Eli Lilly and Company